What records are connected here?
- Evidence lanes
- 3
- Source years
- 18
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Limited human dataNot a peptideHormones · Bone and growth
Also called Increlex1
Not a peptide: a protein, larger than a peptide, often looked up alongside peptides.
Mecasermin is recombinant human insulin-like growth factor 1 (IGF-1), a 70-amino-acid protein identical to the body’s own, and the active ingredient in Increlex. At 70 amino acids it is a protein under FDA’s definition, not a peptide.1,3 FDA approved Increlex in 2005 to treat growth failure in children aged 2 and older with severe primary IGF-1 deficiency, or with growth hormone gene deletion and antibodies that block growth hormone.1,2 In five studies of 71 children, growth rate rose from 2.8 cm a year before treatment to 8.0 cm in the first year. The label has no boxed warning but warns of severe low blood sugar.1
| Substance type | Not a peptide. The Increlex label states that mecasermin is a single chain of 70 amino acids, and FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids.1,3 |
|---|---|
| What it is | Human IGF-1 made by recombinant DNA technology in bacteria: a single chain of 70 amino acids with three disulfide bridges, according to the label.1 |
| FDA status | FDA-approved. Drugs@FDA lists Increlex, application 021839, with an original approval date of August 30, 2005. The label has no boxed warning.1,2 |
| Human evidence | Five studies in 71 children with severe primary IGF-1 deficiency, four of them open-label, pooled in the label.1 |
| Evidence strength | Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned |
Mecasermin is human insulin-like growth factor 1 made by recombinant DNA technology in E. coli bacteria. The label states that it is a single chain of 70 amino acids with the same sequence as the body’s own IGF-1.1
FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids, so mecasermin counts as a protein, not a peptide.1,3
In the United States it is the active ingredient of Increlex, approved under application 021839, according to Drugs@FDA.2
Growth hormone normally makes the liver and other tissues produce IGF-1, which acts on the type 1 IGF-1 receptor to drive growth in height, according to the label. Mecasermin supplies IGF-1 directly.1
The label states that IGF-1 also has insulin-like effects on glucose uptake, which is why low blood sugar is its main warning.1
The label pools five studies, four open-label and one double-blind and placebo-controlled, in 71 children with severe primary IGF-1 deficiency, most of whom had Laron syndrome.1
Mean growth rate was 2.8 cm a year before treatment, 8.0 cm in the first year and 5.8 cm in the second, and remained above the pre-treatment average, by smaller margins, in the children followed for longer.1
Evidence-strength label: Limited human data. How this label is assigned
Yes. Drugs@FDA lists Increlex, application 021839, with an original approval date of August 30, 2005.2
The Increlex label cited here (DailyMed SPL version 4, published November 17, 2025) states that it is indicated for growth failure in children 2 years and older with severe primary IGF-1 deficiency, or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone, and that it is not a substitute for growth hormone.1
The label has no boxed warning. It warns that severe low blood sugar, including seizures, has been seen with Increlex, and also warns of serious allergic reactions.1
How it affects final adult height compared with no treatment: most of the label’s studies were open-label and had no untreated comparison group.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Mecasermin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Mecasermin are a bounded selection, not every registration or paper about Mecasermin. For the years before Mecasermin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Mecasermin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Mecasermin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Increlex for severe primary IGF-1 deficiency in children. Approval rests on five studies in 71 children, mostly open-label, in which growth rate rose in the first year of treatment. The label warns of severe low blood sugar.↗↗
Status sources checked through November 16, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Increlex for severe primary IGF-1 deficiency in children. Approval rests on five studies in 71 children, mostly open-label, in which growth rate rose in the first year of treatment. The label warns of severe low blood sugar.↗↗
The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 5, 2026
Mecasermin for the treatment of Rett Syndrome: a systematic review.↗Added to PeptideScanner November 16, 2026Regulatory · added November 17, 2026
Federal Register notice E6-12571↗Source date August 3, 2006Regulatory · added November 17, 2026
Federal Register notice E6-9138↗Source date June 13, 2006Regulatory · added November 17, 2026
Drugs@FDA application BLA021839↗Source date August 30, 2005PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
8 of 9 selected trial records include at least one phase value; 9 of 9 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
18 of 18 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
The official Drugs@FDA dataset lists original submission 1 for BLA 021839 with status AP dated 2005-08-30, and names mecasermin recombinant among the application record's active ingredients.
The Federal Register published notice 97-10541, attributed to FDA and its parent HHS department, on 1997-04-23. Its official title is “Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.
The Federal Register published notice 98-7053, attributed to FDA and its parent HHS department, on 1998-03-19. Its official title is “Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.
18 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span April 23, 1997 to November 5, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 41174329 in Neurogenetics as Journal Article, Systematic Review, with publication-date metadata of 2025-11-01 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00903110 at 2026-11-16T17:35:13.282Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was mecasermin.↗
Literature metadata
PubMed lists PMID 36269524 in Stem cell reviews and reports as Journal Article, with publication-date metadata of 2022-10-21 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02636270 at 2026-11-16T17:35:13.282Z. Its registry update date was 2024-02-28, and PeptideScanner's reviewed identity mapping was mecasermin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00571727 at 2026-11-16T17:35:13.282Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was mecasermin.↗
Literature metadata
PubMed lists PMID 36479333 in Australian prescriber as Journal Article, Review, with publication-date metadata of 2022-12-01 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 18481900 in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy as Journal Article, Review, with publication-date metadata of 2008 (year precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 19707272 in Therapeutics and clinical risk management as Journal Article, with publication-date metadata of 2009-08-03 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00516386 at 2026-11-16T17:35:13.282Z. Its registry update date was 2021-11-18, and PeptideScanner's reviewed identity mapping was mecasermin.↗
Literature metadata
PubMed lists PMID 32692415 in Biotechnology and applied biochemistry as Journal Article, with publication-date metadata of 2020-08-07 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 29750649 in Journal of pediatric endocrinology & metabolism : JPEM as Case Reports, Journal Article, with publication-date metadata of 2018-06-27 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 26339260 in Research in pharmaceutical sciences as Journal Article, with publication-date metadata of 2014 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
Federal Register · Official source · Source checked November 16, 2026